Select Airway Specialized Pro-Resolving Mediators Are Associated with Recovery from Non-Viral COPD Exacerbations.

Rationale: Recovery from chronic obstructive pulmonary disease (COPD) exacerbations is heterogeneous and has a profound impact on disease trajectories. Resolution of airway inflammation is an active process which may be driven by Specialized Pro-resolving Mediators (SPMs).

Objectives: To characterize the temporal change in SPMs in the sputum of COPD patients during COPD exacerbations, their association with exacerbation triggers and exacerbation recovery.

Chronic norovirus infection in immunodeficiency: a UK national case series.

Chronic norovirus infection can lead to significant diarrhoea, malabsorption, and weight loss in immunodeficiency. The clinical and histological picture in these patients is remarkably similar, suggesting that the virus is a main driver for the enteropathy.

Impact of patient-family physician language concordance on healthcare utilisation and mortality: a retrospective cohort study of home care recipients in Ontario, Canada.

Introduction: As the world's linguistic diversity continues to increase at an unprecedented rate, a growing proportion of patients will be at risk of experiencing language barriers in primary care settings. We sought to examine whether patient-family physician language concordance in a primary care setting is associated with lower rates of hospital-based healthcare utilisation and mortality.

Methods: We conducted a population-based retrospective cohort study of 497 227 home care recipients living in Ontario, Canada.

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.

Novel selective estrogen receptor degraders (SERDs) are a promising therapeutic option under investigation for patients with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The efficacy of novel SERDs in the treatment of advanced disease has prompted investigation into their use in the early disease setting, to reduce breast cancer recurrence. Here, we describe the design and rationale of the phase III, randomized, open-label CAMBRIA-1 and CAMBRIA-2 studies.

Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS).

Background: Despite current antiplatelet therapy, patients remain at risk of recurrent ischemic events after acute coronary syndromes (ACS), which may reflect persistently elevated thrombin generation. Factor XIa inhibition reduces thrombin generation and may improve clinical outcomes with minimal bleeding risk.

Design: Librexia ACS (ClinicalTrials.